Brief: Aprea Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
01/03/2023 22:08
March 1 (Reuters) - Aprea Therapeutics Inc APRE.O :
* APREA THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ MINIMUM
BID
PRICE REQUIREMENT
Source text for Eikon: ID:nGNX4LqFwl
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing